Lindsey Roeker, MD

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Lindsey Roeker, MD, spoke about phase 2 trial results which demonstrated efficacy of the combination of umbralisib and ublituximab added to ibrutinib for patients with chronic lymphocytic leukemia.

Lindsey Roeker, MD, spoke about using a combination that includes a Bruton tyrosine kinase inhibitor, PI3K inhibitor, and an anti-CD20 monoclonal antibody for patients with chronic lymphocytic leukemia.

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.